Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

ADVM - Adverum Biotechnologies, Inc.

IEX Last Trade
4.82
-0.020   -0.415%

Share volume: 2,794
Last Updated: Fri 27 Dec 2024 08:30:16 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 0.25%

PREVIOUS CLOSE
CHG
CHG%
$4.84
-0.02
-0.41%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
8%
Profitability 8%
Dept financing 4%
Liquidity 50%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
5.91%
1 Month
-22.17%
3 Months
-27.67%
6 Months
-28.08%
1 Year
-33.33%
2 Year
-7.04%
Key data
Stock price
$4.82
P/E Ratio 
0.00
DAY RANGE
$4.81 - $5.09
EPS 
$0.00
52 WEEK RANGE
$0.78 - $29.70
52 WEEK CHANGE
-$33.32
MARKET CAP 
144.358 M
YIELD 
N/A
SHARES OUTSTANDING 
20.801 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
0.49
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$244,478
AVERAGE 30 VOLUME 
$235,541
Company detail
CEO: Laurent Fischer
Region: US
Website: adverum.com
Employees: 190
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Adverum Biotechnologies, Inc. develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate. The company was incorporated in 2006 and is headquartered in Redwood City, California.

Recent news